dm+d

Unassigned

New Medicines

EstybonRefractory myelodysplastic syndromes (MDS), high-risk

Information

Estybon
New molecular entity
Baxalta
Onconova

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Yes
Yes
Jan 21No longer listed in company pipeline for MDS; assume all development discontinued in this indication [22].

Category

Phosphatidylinositol 3 kinase inhibitor
Approximately 60-70% of patients are classified as primary myelodysplastic syndrome (MDS). The estimated incidence of MDS increases significantly with age, ranging from 0.7/100,000 during the fourth decade to 20.8-36.3/100,000 in those aged over 70 years. [3]
Refractory myelodysplastic syndromes (MDS), high-risk
Intravenous infusion

Further information

Yes
Suspended

Trial or other data

Aug 20PIII INSPIRE study fails to to meet primary endpoint of significantly improved survival vs best supportive care in higher-risk MDS. In the intent-to-treat analysis, patients randomised to IV rigosertib achieved OS of 6.4 months vs. 6.3 months for physician´s choice (p=0.33) in overall population [20].

Evidence based evaluations